Business Monitor International


Thailand Pharmaceuticals & Healthcare Report

Published 25 April 2014

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Thailand Pharmaceuticals & Healthcare Report

BMI View:  Thailand offers several revenue earning opportunities to drugmakers due to its ageing population and the presence of a universal healthcare system that provides the population with access to healthcare. However cost containment policies and delays in patent approvals limit the attractiveness of the country to multinational pharmaceutical firms.

Headline Expenditure Projections

  • Pharmaceuticals: THB142.5bn (USD4.64bn) in 2013 to THB146.5bn (USD4.5bn) in 2014; +2.8% in local currency terms and -2.8% in US dollar terms. Forecast downgraded from Q314 , although currency fluctuations affected the growth rate in US dollar terms

  • Healthcare: THB473.3bn (USD15.4bn) in 2013 to THB506.7bn (USD15.6bn) in 2014; +7.1% in local currency terms and +1.2% in US dollar terms. Forecast in absolute terms was downgraded due to receipt of data from the World Health Organization currency fluctuations also affected the growth rate in US dollar terms.

Risk/Reward Rating: In Q 4 2014, Thailand is ranked 1 2 th out of the 19 key markets in Asia Pacific. While Thailand's score for its Industry Rewards variable is above the regional average (22.8 versus 21.8), indicating the country's favourable longer-term standing in terms of its pharmaceutical market development, operating risks - including the lacking intellectual property (IP) environment - remain elevated.

Key Trends and Developments

  • Since July 1 2014, the first health centre for migrant workers will be setup in Samut Sakhon province to bring Cambodians into the health insurance system and reduce a burden on the state in the long term. The public health ministry shouldered the burden of unpaid migrant workers' bills (THB300mn).

  • In June 2014, public health officials from Thailand, Vietnam and Indonesia agreed to actively collaborate on a new study on sepsis, which is a major cause of death due to infectious diseases in Southeast Asia. Preliminary results from a Thai study revealed that one in six patients...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2010-2018)
18
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2010-2018)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
26
Thailand
26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
27
OTC Medicine Market Forecast
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2010-2018)
29
Table: OTC Medicine Sales Indicators by Category, 2006-2008
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecast (Thailand 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2012-2018)
32
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: Thailand - Economic Activity
38
Industry Risk Reward Ratings
39
Asia Risk/Reward Ratings
39
Thailand Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Communicable Diseases
50
Healthcare System
50
Healthcare Insurance
52
Recent Health Insurance Developments
53
Medical Tourism
55
Research And Development (R&D)
56
Biosimilars
57
Clinical Trials
58
Regulatory Development
60
Regulatory Regime
60
Regulatory Development
61
Regional Harmonisation
62
Intellectual Property Regime
63
IP Shortcomings
63
IP Developments
65
Pricing And Reimbursement
65
Table: Price Build-Up Of Medicines In Thailand
66
Competitive Landscape
68
Pharmaceutical Industry
68
Domestic Pharmaceutical Industry
69
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
70
Foreign Pharmaceutical Industry
70
Table: PReMA Members
70
Recent Pharmaceutical Industry Developments
70
Pharmaceutical Wholesale
72
Pharmaceutical Retail
73
Company Profile
75
Siam Pharmaceutical
75
Government Pharmaceutical Organisation
77
Biolab
81
Thai Meiji Pharmaceutical Company
83
Berlin Pharmaceutical Industry
85
Pfizer
87
Sanofi
90
GlaxoSmithKline
93
Merck & Co
96
Novartis
99
Demographic Forecast
102
Table: Thailand's Population By Age Group, 1990-2020 ('000)
103
Table: Thailand's Population By Age Group, 1990-2020 (% of total)
104
Table: Thailand's Key Population Ratios, 1990-2020
105
Table: Thailand's Rural And Urban Population, 1990-2020
105
Glossary
106
Methodology
108
Pharmaceutical Expenditure Forecast Model
108
Healthcare Expenditure Forecast Model
108
Notes On Methodology
109

The Thailand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Thailand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Thai pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Thailand to test other views - a key input for successful budgeting and strategic business planning in the Thai pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Thai pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Thailand.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc